Indole-3-propionic acid
|
Basic information |
| Metabolite name | Indole-3-propionic acid |
 | HMDB0002302 |
 |
N/A |
 |
3744 |
| Synonyms | lndole-3-propionic acic; |
| No. of studies | 15 |
|
Basic information |
| Metabolite name | Indole-3-propionic acid |
| HMDB0002302 |
|
N/A |
|
3744 |
| Synonyms | lndole-3-propionic acic; |
| No. of studies | 15 |
|
Relationship between Indole-3-propionic acid and depression (count: 15) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Unknown |
| Study M099 | Type3 | probiotics group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M099 | Type3 | high-fat diet + probiotics group vs. high-fat diet grou | Plasma | Sprague-Dawley rat | Up |
| Study M1008 | Type2 | CCFM1025 group vs. placebo group | Faece | Human | Up |
| Study M104 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + BH group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + ZB group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1072 | Type1 | CUMS group vs. control group | Intestine | Cynomolgus monkey | Up |
| Study M1143 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M120 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M457 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M766 | Type1 | CUS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M861 | Type2 | medication-treated group, posttreatment vs. baseline | Serum | Human | Up |
| Study M861 | Type4 | medication-treated group, remitter vs. nonremitter | Serum | Human | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Down |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M981 | Type2 | Abeta oligomer + acousto-optic stimulation group vs. Abeta oligomer group | Serum | ICR mouse | Up |